This activity will focus on new surgical techniques, incorporating new technology, and advanced case management in corneal refractive, cataract and glaucoma surgery. Additionally, discussions on current and future pharmacologic agents in the management of ocular surface disease, glaucoma and anti-infective’s will be presented. The primary target audience consists of practicing ophthalmologists, optometrists and allied health professionals engaged in the medical and surgical management of patients with corneal diseases, refractive error, presbyopia, cataract and glaucoma conditions. The meeting is particularly geared towards cornea and glaucoma specialists, cataract, glaucoma and anterior segment surgeons.
The goal of the CME activity is to enhance clinical knowledge and patient management strategies for ocular conditions requiring the use of diagnostic technologies, perioperative therapeutics, advanced surgical technologies, and complications management. Presentation of recent and emerging clinical research evidence by expert program faculty will include case discussions along with audience participation in order to enhance the educational format. Case presentations that utilize recorded surgical videos will provide program participants with real examples of expert clinical and surgical decision making skills.
Upon completion of this activity, the participant should be able to:
• Evaluate the latest published literature and meta-analyses to differentiate the benefits/detractors of femtosecond laser for cataract surgery compared to traditional phacoemulsification
• Assess the ability of topical ophthalmic NSAIDs to treat postop inflammation and pain in a cataract patient
• Discuss how to ensure maximum efficacy with toric lenses
• Discuss how to manage visually significant astigmatism
• Evaluate the current and potential future therapies for dry eye disease
• Evaluate the safety and efficacy of different treatment modalities for ocular hypertension and pri-mary open-angle glaucoma
• Discuss future developments and direction of therapeutics and surgical devices for managing glaucoma
• Formulate strategies to manage patients with presbyopia in an integrated care system
• Develop a strategy to improve integrated patient management
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, the American College of Eye Surgeons (ACES), the American Board of Eye Surgery (ABES) and the Society for Excellence in Eyecare (SEE). Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.
Evolve Medical Education, LLC this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Ophthalmologists, optometrists and allied health professionals face increasing pressure to remain current in their clinical knowledge, diagnostic skills and treatment selection due to shifting demographics and increasing numbers of aging patients.
These changes are of particular significance in the areas of refractive surgery, cataract surgical services, cornea services, and glaucoma management. As population trends lead to changes in ocular disease prevalence, ophthalmic development in pharmaceuticals and new medical device technology continues to change the treatment strategies available to clinicians and surgeons. Practice patterns are shifting as well, with practice management embracing the need for integrated management.
In the past 5 years alone, ophthalmology has seen the introduction of femtosecond lasers for cataract surgery, intraoperative aberrometry, enhanced depth of focus intraocular lenses, new IOL calculators, presbyopia-correcting IOLs and corneal inlays, micro-incisional glaucoma surgery (MIGS) and the devices associated with them, a bevy of diagnostic tools to better identify and quantify dry eye, the second dry eye pharmacologic treatment, software improvements on refractive lasers, small incision lenticule extraction (SMILE), and the U.S. approval of collagen corneal crosslinking (CXL).
Ongoing education about these innovations is necessary to provide eye care professionals with the best means to enhance patient outcomes.